中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2015年
13期
147-149
,共3页
寻常型银屑病%阿维A%窄谱中波紫外线%临床疗效
尋常型銀屑病%阿維A%窄譜中波紫外線%臨床療效
심상형은설병%아유A%착보중파자외선%림상료효
Psoriasis vulgaris%Acitretin%Narrow-band ultraviolet B (NB-UVB)%Clinical effect
目的:观察阿维A联合窄谱中波紫外线(NB-NVB)治疗寻常型银屑病的临床疗效情况。方法选取2013年1~12月收治的寻常型银屑病患者112例,随机分为观察组与对照组,对照组患者给予阿维A进行治疗,观察组联合应用NB-NVB进行治疗,对比观察两组临床疗效情况。结果观察组患者治疗后PASI评分明显低于对照组,治愈率、总有效率明显高于对照组,临床起效时间较对照组显著缩短,差异有统计学意义(P<0.05)。结论阿维A与NB-NVB联合治疗寻常型银屑病,能够加快药物发挥,缩短治疗时间,明显提高临床疗效,具有理想的临床应用价值。
目的:觀察阿維A聯閤窄譜中波紫外線(NB-NVB)治療尋常型銀屑病的臨床療效情況。方法選取2013年1~12月收治的尋常型銀屑病患者112例,隨機分為觀察組與對照組,對照組患者給予阿維A進行治療,觀察組聯閤應用NB-NVB進行治療,對比觀察兩組臨床療效情況。結果觀察組患者治療後PASI評分明顯低于對照組,治愈率、總有效率明顯高于對照組,臨床起效時間較對照組顯著縮短,差異有統計學意義(P<0.05)。結論阿維A與NB-NVB聯閤治療尋常型銀屑病,能夠加快藥物髮揮,縮短治療時間,明顯提高臨床療效,具有理想的臨床應用價值。
목적:관찰아유A연합착보중파자외선(NB-NVB)치료심상형은설병적림상료효정황。방법선취2013년1~12월수치적심상형은설병환자112례,수궤분위관찰조여대조조,대조조환자급여아유A진행치료,관찰조연합응용NB-NVB진행치료,대비관찰량조림상료효정황。결과관찰조환자치료후PASI평분명현저우대조조,치유솔、총유효솔명현고우대조조,림상기효시간교대조조현저축단,차이유통계학의의(P<0.05)。결론아유A여NB-NVB연합치료심상형은설병,능구가쾌약물발휘,축단치료시간,명현제고림상료효,구유이상적림상응용개치。
Objective To observe the clinical effect of acitretin combined with narrow-band ultraviolet B (NB-UVB) on treating psoriasis vulgaris. Methods 112 patients with psoriasis vulgaris in our hospital from January to December 2013 were selected and randomly divided into observation group and control group.Only acitretin was provided in control group,while acitretin combined with NB-UVB was applied in control group.The clinical effect between two groups was compared and observed. Results Score of psoriasis area and severity index(PASI) in observation group was greatly lower than that in control group.The cure rate and total effective rate in observation group were higher than that in control group.The onset time in clinic in observation group was obviously shortened.All comparisons between two groups dis-played statistical differences (P<0.05). Conclusion Acitretin combined with NB-UVB in the treatment of psoriasis vul-garis can speed up drug’s use,shorten treatment time,and greatly improve clinical effect,which has an ideal application value in clinic.